According to the North China Pharmaceutical announcement, the cumulative deviation value of the company's stock price increase exceeded 20% for 3 consecutive trading days on September 30, October 8, and October 9, 2026. This is an abnormal fluctuation in stock trading, and continued to rise and stop on October 12. From September 30 to October 12, the company's stock price rose from 4.98 yuan/share to 6.63 yuan/share, an increase of 33.13%, and a cumulative turnover rate of 22.95%. As of October 12, the company's static price-earnings ratio was 62.14, higher than the static price-earnings ratio of 27.04 in the pharmaceutical manufacturing industry. The company's revenue for the first half of 2026 was 4.220 billion yuan, down 20.01% year on year; net profit to mother was 63.8459 million yuan, down 48.30% year on year; net profit after deducting non-return to mother was 585.759 million yuan, down 51.16% year on year. Currently, the company's production and operation are normal, and there is no important information that should be disclosed or not disclosed, reminding investors to pay attention to investment risks.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.